Prosthetic valve thrombosis in pregnancy: A promising treatment for a rare and mostly preventable complication

Circulation

Volumn 128, Issue 5, 2013, Pages 481-482

  Casais, Patricia ^a   Rolandi, Florencia ^b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; BODY TEMPERATURE; DRUG EFFICACY; EDITORIAL; FETUS HEART RATE; FETUS MORTALITY; FETUS WASTAGE; FOLLOW UP; GESTATIONAL AGE; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; INTERNATIONAL NORMALIZED RATIO; NEWBORN MORTALITY; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RECURRENT DISEASE; RISK FACTOR; SECOND TRIMESTER PREGNANCY; TERATOGENESIS; UTERUS CONTRACTION;

ANTICOAGULANTS; EDITORIALS; HEART VALVES; PREGNANCY; THROMBOLYSIS;

FEMALE; HEART DISEASES; HEART VALVE PROSTHESIS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84881103166     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.004259     Document Type: Editorial

References (14)

1. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl):e576S-e600S.
2. Royal College of Obstetricians and Gynaecologists (RCOG). Heart Disease and Pregnancy Study Group statement: Consensus views arising from the 51st Study Group: Heart Disease and Pregnancy: Http://www. rcog.org.uk/womens-health/ clinical-guidance/heart-disease-and-pregnancy-study-group-statement. Accessed June 20, 2013.
3. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçik M, Oǧuz AE, Gündüz S, Astarcioglu MA, Aykan AC, Bayram Z, Biteker M, Kaynak E, Kahveci G, Duran NE, Yildiz M. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013;128:532-540.
4. Jafferani A, Malik A, Khawaja RD, Sheikh L, Sharif H. Surgical management of valvular heart diseases in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2011;159:91-94.
5. Arnoni RT, Arnoni AS, Bonini RC, de Almeida AF, Neto CA, Dinkhuysen JJ, Issa M, Chaccur P, Paulista PP. Risk factors associated with cardiac surgery during pregnancy. Ann Thorac Surg. 2003;76:1605-1608.
6. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl):e691S-e736S.
7. McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: No easy option. Thromb Res. 2011;127(suppl 3):S56-S60.
8. Malik HT, Sepehripour AH, Shipolini AR, McCormack DJ. Is there a suitable method of anticoagulation in pregnant patients with mechanical prosthetic heart valves? Interact Cardiovasc Thorac Surg. 2012;15:484-488.
9. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med. 2000;160:191-196.
10. Elkayam U, Goland S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. J Am Coll Cardiol. 2012;59:1116-1118.
11. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines. ESC guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-3197.
12. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e523-e661.
13. McLintock C. Anticoagulant choices in pregnant women with mechanical heart valves: Balancing maternal and fetal risks: The difference the dose makes. Thromb Res. 2013;131 Suppl 1:S8-10.
14. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368:601-611.